Reuter C - Search Results

1

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk PJ, Krauter J, Ganser A. Damm F, et al. Among authors: reuter c. Blood. 2011 Apr 28;117(17):4561-8. doi: 10.1182/blood-2010-08-303479. Epub 2011 Mar 3. Blood. 2011. PMID: 21372155 Free article.

2

Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia.

Reuter CW, Krauter J, Onono FO, Bunke T, Damm F, Thol F, Wagner K, Göhring G, Schlegelberger B, Heuser M, Ganser A, Morgan MA. Reuter CW, et al. Ann Hematol. 2014 Jun;93(6):977-82. doi: 10.1007/s00277-014-2061-9. Epub 2014 Apr 16. Ann Hematol. 2014. PMID: 24737308

3

Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.

Damm F, Bunke T, Thol F, Markus B, Wagner K, Göhring G, Schlegelberger B, Heil G, Reuter CW, Püllmann K, Schlenk RF, Döhner K, Heuser M, Krauter J, Döhner H, Ganser A, Morgan MA. Damm F, et al. Among authors: reuter cw. Leukemia. 2012 Feb;26(2):289-95. doi: 10.1038/leu.2011.200. Epub 2011 Aug 9. Leukemia. 2012. PMID: 21826063

4

Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.

Morgan MA, Reuter CW. Morgan MA, et al. Ann Hematol. 2006 Mar;85(3):139-63. doi: 10.1007/s00277-005-0051-7. Epub 2006 Jan 4. Ann Hematol. 2006. PMID: 16391911 Review.

5

Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.

Morgan MA, Ganser A, Reuter CW. Morgan MA, et al. Among authors: reuter cw. Leukemia. 2003 Aug;17(8):1482-98. doi: 10.1038/sj.leu.2403024. Leukemia. 2003. PMID: 12886235 Review.

6

Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.

Morgan MA, Dolp O, Reuter CW. Morgan MA, et al. Among authors: reuter cw. Blood. 2001 Mar 15;97(6):1823-34. doi: 10.1182/blood.v97.6.1823. Blood. 2001. PMID: 11238126 Free article.

7

Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.

Morgan MA, Wegner J, Aydilek E, Ganser A, Reuter CW. Morgan MA, et al. Among authors: reuter cw. Leukemia. 2003 Aug;17(8):1508-20. doi: 10.1038/sj.leu.2403022. Leukemia. 2003. PMID: 12886237

8

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

Reuter CW, Morgan MA, Bergmann L. Reuter CW, et al. Blood. 2000 Sep 1;96(5):1655-69. Blood. 2000. PMID: 10961860 Free article. Review.

9

Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.

Morgan MA, Onono FO, Spielmann HP, Subramanian T, Scherr M, Venturini L, Dallmann I, Ganser A, Reuter CW. Morgan MA, et al. J Mol Med (Berl). 2012 Feb;90(2):149-61. doi: 10.1007/s00109-011-0814-7. Epub 2011 Sep 14. J Mol Med (Berl). 2012. PMID: 21915711

10

Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients.

Kappler P, Morgan MA, Ivanyi P, Brunotte SJ, Ganser A, Reuter CWM. Kappler P, et al. Sci Rep. 2021 Aug 12;11(1):16457. doi: 10.1038/s41598-021-95874-y. Sci Rep. 2021. PMID: 34385568 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

473 results

Search Page

Filters